Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Overview


Plain-Language Overview

Chikungunya Fever is a viral illness caused by the Chikungunya virus, which primarily affects the joints and skin. It is transmitted to humans through the bite of infected Aedes mosquitoes. The disease often causes sudden onset of high fever, severe joint pain, and a distinctive rash. The joint pain can be debilitating and may last for weeks to months, affecting daily activities. Other symptoms include headache, muscle pain, and fatigue. This illness mainly impacts the musculoskeletal system and skin, leading to discomfort and reduced mobility during the acute phase.

Clinical Definition

Chikungunya Fever is an acute febrile illness caused by the Chikungunya virus, an alphavirus transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The core pathology involves viral replication in fibroblasts and joint tissues, leading to an intense inflammatory response that manifests as polyarthritis and rash. The disease is characterized by sudden onset of high fever, polyarthralgia or polyarthritis, and a maculopapular rash. The joint symptoms are often symmetric and can mimic rheumatoid arthritis. The infection is self-limited but can cause chronic joint symptoms in some patients. Diagnosis is important due to overlapping symptoms with other arboviral infections like dengue and Zika virus.

Inciting Event

  • Bite from an infected Aedes mosquito transmitting Chikungunya virus.

  • Introduction of virus into the bloodstream initiating systemic infection.

Latency Period

  • Incubation period of 2 to 12 days after mosquito bite before symptom onset.

  • Acute symptoms typically develop within 3 to 7 days post-exposure.

Diagnostic Delay

  • Symptom overlap with dengue and Zika virus infections often leads to initial misdiagnosis.

  • Lack of specific early diagnostic tests in resource-limited settings delays confirmation.

  • Mild or atypical presentations may be mistaken for other viral illnesses or autoimmune arthritis.

  • Low clinical suspicion in non-endemic areas contributes to delayed diagnosis.

Clinical Presentation


Signs & Symptoms

  • High fever with abrupt onset lasting 2-5 days

  • Severe polyarthralgia or polyarthritis causing joint stiffness and swelling

  • Maculopapular rash appearing 2-5 days after fever onset

  • Headache, myalgia, and conjunctivitis frequently accompany systemic symptoms

  • Fatigue and malaise persisting beyond acute illness

History of Present Illness

  • Sudden onset of high fever followed by severe symmetric polyarthritis affecting small joints of hands, wrists, and ankles.

  • Maculopapular rash appears 2 to 5 days after fever onset, often involving the trunk and extremities.

  • Myalgias, headache, and conjunctivitis commonly accompany systemic symptoms.

  • Joint pain may persist for weeks to months, sometimes evolving into chronic arthritis.

  • Symptoms typically resolve within 7 to 10 days, but fatigue and joint stiffness may linger.

Past Medical History

  • Previous arboviral infections such as dengue may influence clinical presentation.

  • History of chronic inflammatory arthritis can complicate diagnosis and management.

  • Immunosuppressive conditions or therapies may alter disease severity.

Family History

  • No known heritable predisposition to Chikungunya virus infection or disease severity.

  • Family clustering may occur due to shared environmental exposure to infected mosquitoes.

Physical Exam Findings

  • Symmetric polyarthritis predominantly affecting small joints of the hands, wrists, and ankles

  • Maculopapular rash often involving the trunk and extremities

  • Tenderness and swelling of affected joints without joint deformity

  • Lymphadenopathy may be present in some cases

  • Conjunctival injection without purulent discharge

Diagnostic Workup


Diagnostic Criteria

Diagnosis of chikungunya fever is established by a combination of clinical presentation and laboratory testing. Key clinical features include acute onset fever, severe polyarthritis or polyarthralgia, and a maculopapular rash. Confirmatory diagnosis relies on detection of Chikungunya virus RNA by RT-PCR during the first week of illness or serologic testing for IgM antibodies after the acute phase. Differential diagnosis includes ruling out other arboviral infections such as dengue and Zika. Elevated inflammatory markers and lymphopenia may support the diagnosis but are nonspecific.

Pathophysiology


Key Mechanisms

  • Infection of fibroblasts and macrophages by Chikungunya virus leads to robust innate immune activation and cytokine release causing systemic inflammation.

  • Viral replication in joint tissues triggers synovial inflammation and polyarthritis resembling rheumatoid arthritis.

  • Endothelial cell infection contributes to vascular permeability and rash development.

  • Adaptive immune response with CD8+ T cell activation and neutralizing antibodies helps clear infection but may contribute to tissue damage.

  • Persistent viral RNA in joint tissues may cause chronic arthritis in some patients.

InvolvementDetails
Organs

Joints are affected by viral-induced inflammation leading to polyarthritis and pain.

Skin manifests the characteristic rash associated with chikungunya fever.

Tissues

Synovial tissue is the primary site of inflammation causing polyarthritis and joint swelling.

Skin is involved due to the characteristic maculopapular rash caused by viral infection.

Cells

Macrophages are infected by the chikungunya virus and contribute to the inflammatory response in joints.

T lymphocytes mediate immune response and contribute to chronic joint inflammation in some cases.

Chemical Mediators

Interleukin-6 (IL-6) is elevated and promotes systemic inflammation and joint symptoms.

Tumor necrosis factor-alpha (TNF-α) contributes to synovial inflammation and joint damage.

Interferon-alpha (IFN-α) is part of the antiviral immune response against the chikungunya virus.

Treatments


Pharmacological Treatments

  • Acetaminophen

    • Mechanism:
      • Inhibits central prostaglandin synthesis to reduce fever and pain.

    • Side effects:
      • Hepatotoxicity with overdose

      • Rare allergic reactions

    • Clinical role:
      • First-line

  • NSAIDs

    • Mechanism:
      • Inhibit cyclooxygenase enzymes to reduce inflammation, pain, and fever.

    • Side effects:
      • Gastrointestinal bleeding

      • Renal impairment

      • Increased cardiovascular risk

    • Clinical role:
      • Second-line

Non-pharmacological Treatments

  • Maintain adequate hydration to prevent dehydration from fever and systemic illness.

  • Rest to reduce joint stress and promote recovery during acute polyarthritis.

  • Use cold compresses to alleviate joint pain and swelling.

Prevention


Pharmacological Prevention

  • No approved antiviral prophylaxis or vaccine currently available for chikungunya virus

  • Symptomatic treatment with acetaminophen or NSAIDs to reduce fever and joint pain

  • Avoidance of aspirin due to bleeding risk in arboviral infections

Non-pharmacological Prevention

  • Mosquito control measures including elimination of standing water to reduce Aedes mosquito breeding

  • Use of insect repellents containing DEET or picaridin to prevent mosquito bites

  • Protective clothing to minimize skin exposure in endemic areas

  • Window screens and bed nets to reduce indoor mosquito contact

  • Public health education on avoiding peak mosquito activity times

Outcome & Complications


Complications

  • Chronic inflammatory arthritis mimicking rheumatoid arthritis

  • Neurological complications including meningoencephalitis and Guillain-Barré syndrome

  • Myocarditis and cardiac arrhythmias in severe cases

  • Hemorrhagic manifestations are rare but possible

  • Secondary bacterial infections due to skin breakdown

Short-term Sequelae Long-term Sequelae
  • Persistent joint pain and swelling lasting weeks to months after acute infection

  • Fatigue and weakness during convalescence

  • Post-viral rash pigmentation changes

  • Transient lymphadenopathy

  • Mild thrombocytopenia and anemia resolving with recovery

  • Chronic polyarthritis resembling seronegative rheumatoid arthritis lasting months to years

  • Joint deformities and functional impairment in severe chronic cases

  • Persistent fatigue and depression impacting quality of life

  • Rare neurological sequelae such as cognitive dysfunction

  • Post-viral autoimmune phenomena

Differential Diagnoses


Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Dengue Fever

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Dengue Fever

Recent travel to tropical areas with high Aedes albopictus mosquito activity

Recent travel to tropical areas with high Aedes aegypti mosquito activity

Fever with prominent polyarthritis and rash, typically without hemorrhagic signs

Abrupt onset of high fever with severe myalgias and retro-orbital headache, often with hemorrhagic manifestations

Mild thrombocytopenia with normal hematocrit

Marked thrombocytopenia and hemoconcentration

Positive chikungunya virus RT-PCR or IgM serology

Positive dengue NS1 antigen or dengue IgM serology

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Rheumatoid Arthritis

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Rheumatoid Arthritis

Acute onset polyarthritis with fever and rash

Chronic symmetric polyarthritis with gradual onset over weeks to months

Negative rheumatoid factor and anti-CCP antibodies

Positive rheumatoid factor and anti-CCP antibodies

Normal joint imaging or transient soft tissue swelling

Joint space narrowing and erosions on X-ray

Symptom resolution with supportive care and NSAIDs

Improvement with disease-modifying antirheumatic drugs (DMARDs)

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Parvovirus B19 Infection

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Parvovirus B19 Infection

Exposure to mosquito bites in endemic areas

Exposure to children with erythema infectiosum (fifth disease)

Fever with maculopapular rash and severe polyarthritis

Mild prodrome followed by slapped-cheek rash and symmetric polyarthritis

Positive chikungunya virus IgM serology

Positive parvovirus B19 IgM serology

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Zika Virus Infection

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Zika Virus Infection

Travel to areas with chikungunya virus transmission

Travel to areas with Zika virus transmission, often overlapping with dengue

High fever with prominent polyarthritis and rash

Mild fever, conjunctivitis, and maculopapular rash with mild arthralgia

Positive chikungunya virus RT-PCR or IgM serology

Positive Zika virus RT-PCR or IgM serology

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus) versus Systemic Lupus Erythematosus (SLE)

Chikungunya Fever (Polyarthritis, Rash - Chikungunya Virus)

Systemic Lupus Erythematosus (SLE)

Acute febrile illness with self-limited polyarthritis and rash

Chronic relapsing-remitting course with multisystem involvement

Negative ANA and normal complement levels

Positive ANA and anti-dsDNA antibodies with hypocomplementemia

Viral infection with chikungunya virus

Autoimmune etiology without infectious cause

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.